Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 17/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 17/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730198 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL6017403 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL14192004 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL11269951 | 0.83 | SLC6A2 (0.41) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL9063835 | 0.82 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1556908 | 0.82 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1590117 | 0.81 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL22230559 | 0.81 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL10584292 | 0.79 | CYP3A4 (0.48) | PTGS1ALDH1A1POLB | |
| SCHEMBL5099274 | 0.79 | ALDH1A1 (0.60) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-4337264-A | ANALGESICS, ANTIINFLAMMATORY AGENTS AND FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1982-06-29 | — | — | US | disclosed |
| US-4316850-A | ANTINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-02-23 | — | — | US | disclosed |
| US-4264619-A | Tertiary aminoacids | CIBA-GEIGY CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| US-4163788-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |
| US-4126691-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRK1, OPRD1, OPRL1 | AKR1C3 885/4885AKR1C2 1676/4885AKR1C1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.